Completed PHASE1 INTERVENTIONAL NCT00185003

Blockade of Vascular Potassium Channels During Human Endotoxemia

Sponsor: Radboud University Medical Center

Interventions L-NMMA Potassium channel blockers: TEA, Quinin, Tolbutamide endotoxin

Updated 6 times since 2017 Last updated: Oct 16, 2008 Started: Jan 31, 2003 Primary completion: Jun 30, 2005 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00185003, this PHASE1 trial focuses on Endotoxemia and remains completed. Sponsored by Radboud University Medical Center, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.